Previous Page  9 / 9
Information
Show Menu
Previous Page 9 / 9
Page Background

Page 54

Notes:

allied

academies

WORLD CONGRESS ON SMART MATERIALS AND STRUCTURES

&

3

rd

International Conference on

POLYMER CHEMISTRY AND MATERIALS ENGINEERING

November 21-22, 2019 | Singapore

Joint event on

Materials Science and Nanotechnology | Volume: 03

Drug delivery systems based on PCL nanoparticles obtained by non-aqueous emulsion

polymerization

Leonard Ionut Atanase

Apollonia University, Romania

C

ancer remains one of the world’s most devastating

diseases responsible for more than 20% of all deaths.

The conventional cancer treatments are generally

associated with a series of toxic side effects: cytotoxicity,

neurotoxicity, nephrotoxicity. In order to minimize these

drawbacks, the achievement of reliable and efficient

delivery systems of therapeutics, by the means of

nanotechnology, is highly recommended.

Drug delivery systems can play a key role in the fight

against cancers by delivering locally the anticancer

drugs, and the efficiency of this delivery depends

on several factors, such as: drug bioavailability, drug

absorption processes, pharmacokinetic processes, timing

for optimal drug delivery. The nanoparticles (NPs) are

based on biocompatible polymers and their advantages

are high drug encapsulation efficiency; improved drug

bioavailability; solubility and retention time; enhanced

chemical and biological stability; controlled drug release

rate; wide variety of administration routes.

New controlled drug delivery systems based on poly(Ɛ-

caprolactone) (PCL) biocompatible NPs were prepared

by a non-aqueous emulsion polymerization starting

from CL-in-PDMS non-aqueous emulsions stabilized with

tailor-made PDMS-b-PCL block copolymers. In this type of

emulsion, usually designated as oil-in-oil (o/o) emulsion,

the monomer droplets are dispersed in a non-miscible

oil and the stabilization can be achieved by using suitable

block copolymers. After the polymerization reaction, the

size of the obtained PCL particles, in the absence and in the

presence of a model drug, was determined by DLS.

e:

leonard.atanase@yahoo.com